Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.

Publication Type:
Journal Article
Multiple sclerosis (Houndmills, Basingstoke, England), 2016, 22 (14), pp. 1883 - 1887
Issue Date:
Full metadata record
Files in This Item:
Filename Description Size
MSJ636959.pdfAccepted Manuscript Version604.32 kB
Adobe PDF
No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier.To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production.In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro.Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.
Please use this identifier to cite or link to this item: